RNCS Free Assessment
Medical Device Registration in Europe · 4.4

Clinical Evaluation Under EU MDR

Next: Post-Market Surveillance Under EU MDR: What Happens After the CE Mark →

In the evolving landscape of the European Union Medical Device Regulation (EU MDR 2017/745), clinical evaluation has become more than a regulatory requirement — it’s a demonstration of trust, transparency, and accountability.

Manufacturers are now expected to go beyond simple claims of safety and performance and build robust clinical evidence that withstands the highest level of scrutiny from Notified Bodies and Competent Authorities. Every manufacturer claims their device is safe and performs as intended. Clinical evaluation proves it with evidence, not assertion.

What is clinical evaluation?

Clinical evaluation is the systematic and planned process to continuously generate, collect, analyse and assess the clinical data pertaining to a device in order to verify the safety and performance, including clinical benefits, of the device when used as intended by the manufacturer. Its aim is to confirm that the device meets the relevant General Safety and Performance Requirements, that the benefits outweigh the risks, and that any claims you make are supported. Article 61 and Annex XIV of the MDR set out the requirements.

It forms a cornerstone of the technical documentation and is directly tied to the device’s risk classification and intended purpose. In essence, clinical evaluation answers three key questions:

  • Is the device safe?
  • Does it perform as intended?
  • Are the benefits greater than the risks?

It is not a one-off report. The report you submit is a snapshot of a process that should run for as long as the device is on the market.

Why it matters

Under the old directives, clinical evaluation was often treated as a literature summary written near the end. The MDR changed that. Reviewers now expect a clear plan, a defensible method, honest appraisal of the data, measurable outcomes, and a conclusion that follows from the evidence.

A weak clinical evaluation can extend the notified body review, because it would trigger questions that can only be answered with more data, and data takes time to generate. A strong clinical evaluation can ensure smoother review.

The clinical evaluation process

MEDDEV 2.7/1 revision 4 describes clinical evaluation in detail. In simple terms, clinical evaluation includes the below stages:

  • Plan: Write a clinical evaluation plan covering the intended purpose, the requirements that need clinical data, the clinical benefits you will demonstrate, the methods and the state of the art.
  • Identify the data: Gather data from your own clinical investigations, literature on the device or equivalent devices, and other relevant clinical experience. Our team can support you with in depth literature search.
  • Appraise the data: Judge each data source for relevance and quality. It important to note that not all evidence carries equal weight.
  • Analyze the data: Ask whether, together, the data demonstrates safety, performance and a favourable benefit-risk profile of your device.
  • Report: Document the conclusion in the clinical evaluation report.
  • Update: Feed data from literature and post-market data throughout the device's lifetime.

Reading the report

A reviewer reading your clinical evaluation report is asking a few simple questions. What is the device for, and who is it for? What clinical benefits do you claim, and how are they measured? What do the data say about safety and performance? How do you know the evidence is sufficient? What is the state of the art, and does your device compare well against it?

If each question has a clear answer with a traceable source, you are in good shape. Otherwise, expect a challenge.

Equivalence: harder than it used to be

Many manufacturers lean on clinical data from an equivalent device. The MDR allows this, but the conditions are more stringent. You must show technical, biological and clinical equivalence, and show that any differences would not affect safety or performance.

For implantable and Class III devices, relying on another manufacturer's equivalent device generally requires a contract giving ongoing access to that manufacturer's technical documentation. Without it, the claim is hard to sustain. MDCG 2020-5 explains how equivalence should be assessed and is worth reading before you build an argument on it.

For more details on equivalence read or blog- Equivalence Under EU MDR: A Regulatory Pathway to Clinical Evidence

Common Challenges Under EU MDR

While clinical evaluation was also part of the former MDD, the MDR sets a much higher bar for evidence quality. Common challenges include:

  • Limited clinical data for legacy devices.
  • Difficulty demonstrating equivalence due to stricter criteria.
  • Increased expectations for ongoing clinical evidence through PMCF.
  • Enhanced scrutiny by Notified Bodies demanding traceability and justification.

Manufacturers can overcome these challenges by adopting a strategic, data-driven approach — integrating regulatory, clinical, and post-market teams early in the process.

Mistakes worth avoiding

  • Writing the plan after the report, rather than before
  • Claiming equivalence without evidence for each characteristic
  • Including favourable studies and quietly leaving out unfavourable ones
  • Treating the literature search as a formality
  • Making claims in marketing that the clinical data do not support
  • Not updating the evaluation after post-market findings

Best Practices for a Defensible Clinical Evaluation

Start Early: Incorporate clinical evaluation planning during device design and development. ✅ Be Transparent: Clearly justify data sources, methodologies, and limitations. ✅ Stay Current: Regularly update the CER with PMS and PMCF data. ✅ Engage Experts: Involve qualified clinical evaluators familiar with the device technology and clinical domain. ✅ Document Everything: Maintain a clear audit trail linking all evidence to GSPR compliance.

Keeping it current

Clinical evaluation does not end at certification. Post-market surveillance and post-market clinical follow-up (PMCF) feed new data back in. For Class III and implantable devices, the PMCF evaluation report and the summary of safety and clinical performance must be updated at least annually. For other classes, update as the data warrant and at least often enough to stay accurate.

If a complaint trend, a new publication or a change in the state of the art alters your benefit-risk picture, the evaluation must change with it.

Not sure your evidence is enough?

We help manufacturers plan, write and maintain clinical evaluations that hold up to Notified Body review. Send us your current evidence and we will give you a straight view on gaps.

Last reviewed: October 2026

Contact us today

Tell us about your device and target market. Our regulatory specialist, not a salesperson, will reply within one business day.

Get Your Free Regulatory Assessment